

## Osteoporosis Management in Women Who Had a Fracture (OMW)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for osteoporosis management in women (OMW).

### What Is the Measure?

The percentage of women between the age of 67 and 85 who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

#### Notes:

- Measurement year for OMW is a 12-month (one-year) window that begins with the identification of the initial fracture between July 1 of the year prior to the measurement year and June 30 of the measurement year.
- A prescription is considered active if the “day’s supply” indicated on the date when the member was dispensed the prescription is the number of days or more between that date and the relevant service date.
- Fractures of finger, toe, face, skull are not included in this measure.
- The intake period is July 1 of the year prior to the measurement year to June 30 of the measurement year. The intake period is used to capture the first fracture.

### What Meets the Measure Requirements?

Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:

- A BMD test, in any setting, on the date of the fracture or in the 180 days following the fracture  
**CPT Code:** 76977-77081, 77085, 77086
- Osteoporosis therapy on the date of the fracture or in the 180 days following the fracture
- A dispensed prescription to treat osteoporosis on the date of the fracture or in the 180 days following the fracture

#### Osteoporosis Medications

Description	Prescription
Bisphosphonates	<ul style="list-style-type: none"> <li>• Alendronate</li> <li>• Alendronate-cholecalciferol</li> <li>• Risedronate</li> <li>• Ibandronate</li> <li>• Zoledronic acid</li> </ul>
Other agents	<ul style="list-style-type: none"> <li>• Abaloparatide</li> <li>• Denosumab</li> <li>• Raloxifene</li> <li>• Romosozumab</li> <li>• Teriparatide</li> </ul>

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.  
108768 0124R

## Required Exclusions

- Members who used hospice services or elect to use a hospice benefit anytime during the measurement year.  
**HCPCS Codes:** G0182, G9473-G9479, Q5003-Q5008, Q5010, S9126, T2042-T2046  
**CPT Codes:** 99377, 99378
- Members who die during the measurement year
- Members who received palliative care anytime during the intake period through the end of the measurement year.  
**HCPCS Codes:** G9054, M1017
- Members 67 to 80 years old as of December 31 of the measurement year with frailty and advanced illness.

Members must meet both frailty and advanced illness criteria to be excluded.

- **Frailty:** At least two indications of frailty with different dates of service during the intake period through the end of the measurement year.
- **Advanced Illness:** Either of the following during the measurement year or the year prior to the measurement
  - Advanced illness on at least two different dates of service
  - Dispensed dementia medication

### Dementia Medications

Description	Prescription
Cholinesterase inhibitors	• Donepezil      • Galantamine      • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine

- Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty with different dates of service during the intake period through the end of the measurement year.

Content reproduced with permission from HEDIS® MY2024, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications).